Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins
Authors
Keywords
-
Journal
Science Signaling
Volume 11, Issue 543, Pages eaaq1077
Publisher
American Association for the Advancement of Science (AAAS)
Online
2018-08-15
DOI
10.1126/scisignal.aaq1077
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design
- (2017) Katherine L. Lee et al. JOURNAL OF MEDICINAL CHEMISTRY
- Toll-like receptors: promising therapeutic targets for inflammatory diseases
- (2016) Asma Achek et al. ARCHIVES OF PHARMACAL RESEARCH
- Toll-like receptors and chronic inflammation in rheumatic diseases: new developments
- (2016) Leo A. B. Joosten et al. Nature Reviews Rheumatology
- Mechanism and Regulation of NLRP3 Inflammasome Activation
- (2016) Yuan He et al. TRENDS IN BIOCHEMICAL SCIENCES
- Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4
- (2015) William T. McElroy et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of potent, selective, and orally bioavailable inhibitors of interleukin-1 receptor-associate kinase-4
- (2015) Zhulun Wang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system
- (2015) Matthew C. Walsh et al. IMMUNOLOGICAL REVIEWS
- Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
- (2015) Priscilla N. Kelly et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain
- (2015) Pragnesh Mistry et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation
- (2015) William T. McElroy et al. ACS Medicinal Chemistry Letters
- Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4
- (2015) Jongwon Lim et al. ACS Medicinal Chemistry Letters
- Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4
- (2014) L. Nathan Tumey et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Interleukin 1/Toll-like Receptor-induced Autophosphorylation Activates Interleukin 1 Receptor-associated Kinase 4 and Controls Cytokine Induction in a Cell Type-specific Manner
- (2014) Leah Cushing et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Quantitative Proteomic Analysis of the Influenza A Virus Nonstructural Proteins NS1 and NS2 during Natural Cell Infection Identifies PACT as an NS1 Target Protein and Antiviral Host Factor
- (2014) K. Tawaratsumida et al. JOURNAL OF VIROLOGY
- Improved vectors and genome-wide libraries for CRISPR screening
- (2014) Neville E Sanjana et al. NATURE METHODS
- The cellular thermal shift assay for evaluating drug target interactions in cells
- (2014) Rozbeh Jafari et al. Nature Protocols
- Ischemia/reperfusion activates myocardial innate immune response: the key role of the toll-like receptor
- (2014) Gemma Vilahur et al. Frontiers in Physiology
- Hematopoietic progenitor cell lines with myeloid and lymphoid potential
- (2013) Vanessa Redecke et al. NATURE METHODS
- Molecular mechanisms for the subversion of MyD88 signaling by TcpC from virulent uropathogenic Escherichia coli
- (2013) G. A. Snyder et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans
- (2012) Horst von Bernuth et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- TLR7 and TLR9 in SLE: when sensing self goes wrong
- (2012) T. Celhar et al. IMMUNOLOGIC RESEARCH
- A20-binding inhibitor of NF- B (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein activation and protects from inflammatory disease
- (2011) J. Zhou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling
- (2010) Su-Chang Lin et al. NATURE
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Toll-like receptors and innate immunity
- (2009) Himanshu Kumar et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines
- (2008) George M. Buckley et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- IRAK-4 inhibitors. Part II: A structure-based assessment of imidazo[1,2-a]pyridine binding
- (2008) George M. Buckley et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Gene-specific control of the TLR-induced inflammatory response
- (2008) Simmie L. Foster et al. CLINICAL IMMUNOLOGY
- Identification of a Potent, Selective, and Orally Active Leukotriene A4Hydrolase Inhibitor with Anti-Inflammatory Activity
- (2008) Cheryl A. Grice et al. JOURNAL OF MEDICINAL CHEMISTRY
- Origin and physiological roles of inflammation
- (2008) Ruslan Medzhitov NATURE
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
- (2008) Jürgen Cox et al. NATURE BIOTECHNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started